Array Biopharma Inc (NASDAQ: ARRY) shares declined 22.7% to $3.44. AstraZeneca reported that its Phase III trial of selumetinib in non-small cell lung cancer did not meet primary endpoint. Array BioPharma was informed of these results on Monday. Share volume was 8.1 million, compared to an all-day average of 1.9 million
